GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valbiotis SA (XPAR:ALVAL) » Definitions » Debt-to-Revenue

Valbiotis (XPAR:ALVAL) Debt-to-Revenue : 6.99 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Valbiotis Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Valbiotis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.11 Mil. Valbiotis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.77 Mil. Valbiotis's annualized Revenue for the quarter that ended in Dec. 2023 was €0.98 Mil. Valbiotis's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 6.99.


Valbiotis Debt-to-Revenue Historical Data

The historical data trend for Valbiotis's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valbiotis Debt-to-Revenue Chart

Valbiotis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 52.48 2.27 25.48 9.15 1.45

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.31 5.65 23.93 0.79 6.99

Competitive Comparison of Valbiotis's Debt-to-Revenue

For the Biotechnology subindustry, Valbiotis's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valbiotis's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valbiotis's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Valbiotis's Debt-to-Revenue falls into.



Valbiotis Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Valbiotis's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.107 + 4.773) / 4.733
=1.45

Valbiotis's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.107 + 4.773) / 0.984
=6.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Valbiotis Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Valbiotis's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Valbiotis (XPAR:ALVAL) Business Description

Traded in Other Exchanges
Address
12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Valbiotis (XPAR:ALVAL) Headlines

No Headlines